Aldosterone, the Mineralocorticoid Receptor, and Cardiovascular Disease in Obesity
Status:
Recruiting
Trial end date:
2025-11-30
Target enrollment:
Participant gender:
Summary
This study will evaluate whether the mineralocorticoid receptor antagonist eplerenone, when
compared to chlorthalidone plus potassium chloride, can improve cardiac MRI-derived
myocardial perfusion reserve and fibrosis, independent of blood pressure, and proportionately
to the severity of autonomous aldosterone production.